An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy
Emmanuel S. Antonarakis(Johns Hopkins University), Mario A. Eisenberger(Johns Hopkins University)
Cited by 107
Related Papers
Bilateral Orchiectomy with or without Flutamide for Metastatic Prostate Cancer
|New England Journal of Medicine|1998|868
Use of androgen deprivation therapy in prostate cancer: indications and prevalence
|Asian Journal of Andrology|2012|63